Published in J Clin Endocrinol Metab on November 20, 2013
Metabolic and cardiovascular implications of a metabolically healthy obesity phenotype. Endocrinol Metab (Seoul) (2014) 1.09
Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring) (2015) 1.03
A novel criterion for identifying metabolically obese but normal weight individuals using the product of triglycerides and glucose. Nutr Diabetes (2015) 0.92
Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism (2015) 0.90
Changes in Metabolic Health Status Over Time and Risk of Developing Type 2 Diabetes: A Prospective Cohort Study. Medicine (Baltimore) (2015) 0.88
Subclinical atherosclerosis and obesity phenotypes among Mexican Americans. J Am Heart Assoc (2015) 0.87
Visceral and subcutaneous adipose tissue FDG uptake by PET/CT in metabolically healthy obese subjects. Obesity (Silver Spring) (2014) 0.87
Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obes (Lond) (2014) 0.85
Insulin resistance is associated with epigenetic and genetic regulation of mitochondrial DNA in obese humans. Clin Epigenetics (2015) 0.82
Prediction of remission after metabolic surgery using a novel scoring system in type 2 diabetes - a retrospective cohort study. J Diabetes Metab Disord (2014) 0.82
Repeated measures of body mass index and C-reactive protein in relation to all-cause mortality and cardiovascular disease: results from the consortium on health and ageing network of cohorts in Europe and the United States (CHANCES). Eur J Epidemiol (2014) 0.81
Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int J Obes (Lond) (2015) 0.79
Obesity Severity and Duration Are Associated With Incident Metabolic Syndrome: Evidence Against Metabolically Healthy Obesity From the Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab (2016) 0.78
Obesity, metabolic health, and mortality in adults: a nationwide population-based study in Korea. Sci Rep (2016) 0.78
Prevalence and clinical characteristics of metabolically healthy obese individuals and other obese/non-obese metabolic phenotypes in a working population: results from the Icaria study. BMC Public Health (2016) 0.78
Definitions of Metabolic Health and Risk of Future Type 2 Diabetes in BMI Categories: A Systematic Review and Network Meta-analysis. Diabetes Care (2015) 0.78
Metabolic Health Has Greater Impact on Diabetes than Simple Overweight/Obesity in Mexican Americans. J Diabetes Res (2016) 0.77
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metab Syndr Relat Disord (2015) 0.77
Predictive Value of Triglyceride Glucose Index for the Risk of Incident Diabetes: A 4-Year Retrospective Longitudinal Study. PLoS One (2016) 0.77
Adenovirus36 infection expresses cellular APMI and Visfatin genes in overweight Uygur individuals. Diagn Pathol (2014) 0.76
Natural Course of Metabolically Healthy Overweight/Obese Subjects and the Impact of Weight Change. Nutrients (2016) 0.76
Risk of the Development of Diabetes and Cardiovascular Disease in Metabolically Healthy Obese People: The Korean Genome and Epidemiology Study. Medicine (Baltimore) (2016) 0.76
Relationship between body weight and the increment in serum brain-derived neurotrophic factor after oral glucose challenge in men with obesity and metabolic syndrome: A prospective study. Medicine (Baltimore) (2016) 0.75
Regulators of mitochondrial quality control differ in subcutaneous fat of metabolically healthy and unhealthy obese monkeys. Obesity (Silver Spring) (2017) 0.75
TyG Index Change Is More Determinant for Forecasting Type 2 Diabetes Onset Than Weight Gain. Medicine (Baltimore) (2016) 0.75
Impact of Obesity on Complications of Laparoscopic Simple or Radical Nephrectomy. Curr Urol (2015) 0.75
Metabolic syndrome among non-obese adults in the teaching profession in Melaka, Malaysia. J Epidemiol (2016) 0.75
A panel of free fatty acid ratios to predict the development of metabolic abnormalities in healthy obese individuals. Sci Rep (2016) 0.75
Metabolically healthy obese women have longer telomere length than obese women with metabolic syndrome. PLoS One (2017) 0.75
Metabolically healthy obesity: a friend or foe? Korean J Intern Med (2017) 0.75
Cardiometabolic Abnormalities Among Normal-Weight Persons From Five Racial/Ethnic Groups in the United States: A Cross-sectional Analysis of Two Cohort Studies. Ann Intern Med (2017) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003) 25.44
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation (1983) 12.63
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med (2003) 10.84
The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med (2008) 9.95
Bariatric surgery and long-term cardiovascular events. JAMA (2012) 7.11
Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes (1993) 5.70
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med (2002) 5.10
Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation (2009) 4.78
The metabolically obese, normal-weight individual revisited. Diabetes (1998) 3.52
Insulin-sensitive obesity. Am J Physiol Endocrinol Metab (2010) 3.46
Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care (2013) 3.43
Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab (2012) 3.26
Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab (2004) 3.18
The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J (2012) 3.02
Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J (2009) 2.71
The "metabolically-obese," normal-weight individual. Am J Clin Nutr (1981) 2.71
Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia (2008) 2.64
Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care (2010) 2.42
Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diabetes Care (2009) 2.26
Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes (2001) 2.10
Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) (2011) 2.00
Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care (2013) 1.93
Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol (1985) 1.89
Higher mortality in metabolically obese normal-weight people than in metabolically healthy obese subjects in elderly Koreans. Clin Endocrinol (Oxf) (2013) 1.88
Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ (2005) 1.86
Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care (2003) 1.49
Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring) (2011) 1.45
Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes (2012) 1.45
Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity (Silver Spring) (2008) 1.42
Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab (2013) 1.41
Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J Lipid Res (2012) 1.26
Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia (2010) 1.14
Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care (2002) 1.07
Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. Asia Pac J Clin Nutr (2012) 1.04
Obesity rising to alarming levels around the world. Lancet (2002) 1.04
Influence of duration of obesity on the insulin resistance of obese non-diabetic patients. Int J Obes Relat Metab Disord (1998) 0.92
Metabolically obese status with normal weight is associated with both the prevalence and severity of angiographic coronary artery disease. Metabolism (2013) 0.91
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol (2004) 6.53
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation (2003) 5.70
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care (2003) 5.27
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes (2003) 5.11
Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med (2002) 5.10
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes (2005) 4.81
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2002) 4.58
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care (2004) 3.51
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care (2002) 2.92
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 2.76
Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.63
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care (2005) 2.53
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes (2009) 2.51
Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol (2003) 2.51
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation (2005) 2.46
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes (2005) 2.42
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care (2007) 2.42
The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes (2006) 2.40
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes (2003) 2.22
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care (2002) 2.16
Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol (2003) 2.12
Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation (2005) 2.08
Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes (2004) 2.08
Sleep duration as a risk factor for incident type 2 diabetes in a multiethnic cohort. Ann Epidemiol (2009) 2.07
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant (2009) 2.02
Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev (2007) 1.98
Dyslipidemia management in adults with diabetes. Diabetes Care (2004) 1.89
Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than homeostasis model assessment or fasting insulin. Diabetes (2003) 1.81
Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metab (2009) 1.81
Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care (2009) 1.78
Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study. Diabetes (2008) 1.78
Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism (2005) 1.77
Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab (2007) 1.76
Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes (2006) 1.75
Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med (2005) 1.71
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst (2012) 1.68
Is prehypertension a risk factor for the development of type 2 diabetes? Diabetes Care (2009) 1.67
Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care (2003) 1.66
Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens (2009) 1.60
Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes (2004) 1.55
Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes (2011) 1.53
Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.53
Analysis of obesity and hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart Study. Obes Res (2002) 1.52
Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes (2004) 1.51
Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev (2007) 1.49
Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic finnish offspring of type 2 diabetic individuals. J Clin Endocrinol Metab (2010) 1.49
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 1.41
A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care (2010) 1.41
Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation (2002) 1.41
Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care (2009) 1.40
Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. J Clin Hypertens (Greenwich) (2012) 1.40
Management of dyslipidemia in adults with diabetes. Diabetes Care (2003) 1.39
Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes (2002) 1.38
Early Pleistocene "hominid remains" from southern Spain and the taxonomic assignment of the Cueva Victoria phalanx. J Hum Evol (2005) 1.38
Analysis of FTO gene variants with measures of obesity and glucose homeostasis in the IRAS Family Study. Hum Genet (2009) 1.36
A population perspective on diabetes prevention: whom should we target for preventing weight gain? Diabetes Care (2003) 1.33
Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation (2003) 1.32
Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes (2004) 1.31
Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring) (2009) 1.28
Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. Med Sci Sports Exerc (2006) 1.27
Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study. Diabetes Care (2009) 1.26
Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care (2010) 1.25
Identification of quantitative trait loci for glucose homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes (2004) 1.25
Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24
Adaptation of Pseudomonas aeruginosa to various conditions includes tRNA-dependent formation of alanyl-phosphatidylglycerol. Mol Microbiol (2008) 1.24
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care (2002) 1.24
Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. Hum Genet (2005) 1.21
A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care (2010) 1.21
Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study. J Clin Endocrinol Metab (2012) 1.21
Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care (2006) 1.20
Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation (2006) 1.17
Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab (2012) 1.15
Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. Diabetes Care (2012) 1.15
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation (2003) 1.15
Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis study. Hypertension (2004) 1.15
Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes (2007) 1.14
Origin of gas retention and symptoms in patients with bloating. Gastroenterology (2005) 1.13
Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care (2007) 1.13
Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index. J Diabetes Complications (2012) 1.12